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An expanded age range for meningococcal
meningitis: molecular diagnostic evidence from
population-based surveillance in Asia
Soon Ae Kim1*†, Dong Wook Kim2,6†, Bai Qing Dong3, Jung Soo Kim4, Dang Duc Anh5 and Paul E Kilgore1,7
Abstract
Background: To understand epidemiologic patterns of meningococcal disease in Asia, we performed a
retrospective molecular analysis of cerebrospinal fluid (CSF) specimens collected in prospective surveillance among
children aged < 5 years of age in China, South Korea, and Vietnam.
Methods: A total of 295 isolates and 2,302 CSFs were tested by a meningococcal species- and serogroup-specific
polymerase chain reaction (PCR) assay targeting the Neisseria meningitidis (Nm) ctrA gene. Multi-locus sequence
typing (MLST) was performed in Nm gene amplification analysis and incidence rates for meningococcal meningitis
were estimated.
Results: Among 295 isolates tested, 10 specimens from Vietnam were confirmed as serogroup B and all were
Sequence Type (ST) 1576 by MLST. Among the 2,032 CSF specimen tested, 284 (14%) were confirmed by PCR (ctrA
gene), including 67 (23.6%) from China, 92 (32.4%) from Korea, and 125 (44.0%) from Vietnam. Neonates and infants
aged < 6 months of age accounted for more than 50% of Nm-PCR positive CSF. Two CSF specimens from Vietnam
were identified as serogroup B using MLST. In addition, 44 specimens underwent sequencing to confirm
meningococcal serogroup; of these, 21 (48%) were serogroup C, 12 (27%) were serogroup X, 9 (20%) were
serogroup Y and 2 (5%) were serogroup B. The incidence rates of meningococcal meningitis among children < 5
years of age was highest in Vietnam (7.4/100,000 [95% CI, 3.6—15.3] followed by Korea (6.8/100,000 [95% CI, 3.5-
13.5] and China (2.1/100,000) [95% CI, 0.7-6.2]).
Conclusions: These results suggest that there is a previously undetected, yet substantial burden of meningococcal
meningitis among infants and young children. Standardized, sensitive and specific molecular diagnostic assays with
Nm serogrouping capacity are needed throughout Asia to understand the true burden of N. meningitidis disease.
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Background
Neisseria meningitidis (N. meningitidis) is a gram-negative,
encapsulated β-proteobacterium and the leading cause
of epidemic meningitis. Globally, N. meningitidis
causes an estimated 1.2 million cases and 135,000
deaths each year [1-3]. In Africa, N. meningitidis is the
leading cause of severe, life-threatening meningitis and is
responsible for thousands of cases and scores of deaths
across sub-Saharan “meningitis belt” countries [4-7].
Moreover, N. meningitidis serogroups A and W-135 have
been exported from Asia to other regions [8]. Previous
studies suggest that these meningococcal serogroups
were carried to the Middle East/Mediterranean region
where meningococcal disease outbreaks subsequently
occurred among Hajj pilgrims and across sub-Saharan
African countries [4,9-12].
In Asia, meningitis outbreaks have been reported in
child-care settings, schools, college dormitories, military
camps, and among returning Hajj pilgrims [8,10,12-15].
Despite these reports documenting sporadic and epi-
demic meningococcal disease, there are large gaps in our
knowledge of meningococcal disease patterns across
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large populations of Asia. It is believed that vaccine intro-
duction against meningococcal disease may have been an
important factor leading to the control of meningococcal
epidemics [16,17], yet there is limited introduction of vac-
cines against meningococcal meningitis in Asian countries
[13]. In addition, the serogroup distribution of meningo-
coccus in Asia is scarce, in part, due to the limited avail-
ability of appropriate diagnostic tests including molecular
assays [13,18]. Here, through the application of molecular
analyses, we provide new evidence of meningococcal
meningitis among hospitalized children < 5 years of age
who were identified during prospective, population-based
surveillance in China, South Korea, and Vietnam.
Methods
Study populations and surveillance
In three study sites, prospective, population-based surveil-
lance for invasive bacterial meningitis in children < 5 years
of age was conducted over a 2-year period. These sites
were located in the Nanning, China (January 2001 -
December 2002), the Jeonbuk Province, South Korea
(September 1999 - December 2001), and Hanoi, Vietnam
(March 2000 - February 2002). In China, children residing
in Nanning, Wuming and Yongning counties of the
Guangxi Province were referred to one of six study
hospitals if they had clinical signs and symptoms of bac-
terial meningitis. In Jeonbuk province, located in the
southwestern region of South Korea, study sites included
the provincial capital city of Jeonju and 10 districts within
the province. In Vietnam, children who resided in any of
the seven urban districts of Hanoi were referred to one of
three central hospitals in Hanoi for study enrollment. Fol-
lowing specimen collection, cerebrospinal fluid (CSF) spe-
cimens were streaked on commercial blood agar culture
media (Becton, Dickinson & Co., Franklin Lakes, USA),
incubated in 5% CO2 at 37°C for 3 days and checked daily
for bacterial growth. After completion of routine bio-
chemical, hematological and microbiological tests, CSF
specimens were preserved at −70°C for further molecular
analysis at the time surveillance conduction. Detailed
methods for these standardized surveillance studies have
been previously described [19-21]. For the analysis of spe-
cimens in this study, we utilized CSF specimens preserved
from the previously conducted surveillance study [19-21].
All CSF specimens utilized in this study were de-identified
prior to laboratory processing and analysis. In the context
of the population-based surveillance study of meningitis
conducted from 1999 to 2002, written consent was not
obtained as the collection of CSF was considered routine
standard of care for hospitalized children with suspected
bacterial meningitis. For this reason, verbal consent of the
parent or legal guardian present with the child during the
hospitalization was recorded in the medical chart of the
patient at the time of the clinical lumbar puncture
procedure. This consenting procedure was approved by
the local scientific ethical review committees of participat-
ing institutions. Ethical approvals for patient specimen
collection during surveillance were obtained from the fol-
lowing institutions: International Vaccine Institute, Seoul,
Korea; Harbor UCLA Medical Center, Torrance, CA,
USA; Jeonbuk National University Hospital, Jeonju, Korea;
Chonju Presbyterian Hospital, Jeonju, Korea; Namwon
Medical Center, Namwon, Korea; Jeongeub Asan Founda-
tion Hospital, Jeongeub, Korea; Won Kwan University
Hospital, Iksan, Korea; National Institute of Hygiene and
Epidemiology, Hanoi, Vietnam; National Institute of
Pediatrics, Hanoi, Vietnam; St. Paul Hospital, Hanoi,
Vietnam; Bach Mai Hospital, Hanoi, Vietnam and the
Guangxi Zhuang Autonomous Region Center for Disease
Control, Nanning, China.
Laboratory testing
The preserved, frozen CSFs and bacterial isolates that
were collected during the prospective meningitis surveil-
lance studies were used for the present analyses. Prior to
molecular analysis of CSF specimens, isolates were sub-
cultured to confirm the bacterial species present in each
specimen. N. meningitidis identification and serogroup
identification were conducted for all bacterial isolates
using multiplex polymerase chain reaction (PCR) target-
ing the ctrA gene [22]. PCR primers used for identifica-
tion of three bacteria (S. pneumoniae, Haemophilus
influenzae type b (Hib), and N. meningitidis) were ctrA
primer sequences from Corless, et al. [23]. HinBF and
HinBR primers for detection of H. influenzae type b using
specific region of bexA gene were designed based on the
report by Corless, et al. [23]. lytA primer sequences were
modified based on a previous report by Llull, et al. [24].
PCR detection sensitivity of ctrA gene was validated by
PCR reaction of serially-diluted reference DNA. Genomic
DNA was prepared from bacterial culture as described
previously [25] and DNA concentration was determined
with a Nano Drop spectrophotometer. The genomic DNA
prep concentration was adjusted to 100 ng/μl and serially-
diluted ten-fold to 1 pg/μl. Based on the genome size of
three serogroups of N. meningitidis (serogroup A, strain
z2491: 2,184,406 bp, serogroup B: 2,272,351 bp, and ser-
ogroup C, strain FAM18: 2,194,961 bp), the molecular
weight of a single copy of N. meningitidis genome was cal-
culated as 2 fg/one genome copy. Two microliters of each
diluted reference DNA were used for template of the PCR
reaction. N. meningitidis genomic DNA was purified from
the bacterial cultures of N. meningitidis-confirmed isolates.
The genomic DNA was further analyzed by two serogroup
identification methods based on the N. meningitidis sialyl-
transferase (siaD) gene and serogroup-specific syn gene
complex [22,26]. Primers used for serotyping of N.
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meningitidis A, B, C, Y, and W135 were designed at the
International Vaccine Institute (Additional file 1: Table S1).
The CSF samples were processed as previously
described [25]. Briefly, 200 μl of each CSF sample was
boiled for 3 minutes and then centrifuged for 5 minutes
at 9,000 × g. The supernatant was removed and put into
a new tube, and 2 μl of the supernatant was used as the
template in the 25 μl PCR reaction. N. meningitidis
PCRs targeting the crgA, IS1106, and 16S rRNA genes were
performed on all MLST-negative CSF specimens to identify
additional N. meningitidis-positive CSF specimens. The
established multi-locus sequence typing (MLST) scheme
(http://pubmlst.org/neisseria/) for Neisseria spp. was used
to analyze bacterial isolates and CSF specimens that
were positive for N. meningitidis specific gene amplifi-
cation analysis. N. meningitidis-specific gene amplifica-
tion analysis of N. meningitidis PCR-positive CSF with
the presence of contact-regulated gene A (crgA),
IS1106, and 16S rRNA was conducted.
Data collection and statistical analysis
For analysis of epidemiologic data, the original study
surveillance database from each field site was merged
with N. meningitidis laboratory results using a unique
study identification number available for each patient.
For age group analysis, patients were grouped into the
following age strata: < 1, 1–6, 7–11, 12–23, 24–35,
36–47, and 48–59 months of age. Children with PCR-
confirmed N. meningitidis were grouped to describe
demographic characteristics, clinical signs and symp-
toms of meningitis, prior use of antibiotics and out-
comes at discharge. Further analysis of results from N.
meningitidis serogroup-specific PCR and sequencing
results were used to describe patient distributions by
clinical characteristics and month of admission. To esti-
mate the incidence of serogrouped N. meningitidis, pre-
viously published population denominator data for
children < 5 years of age were applied for the calcula-
tions of incidence rates [19-21]. Ninety-five percent
confidence limits for incidence rates were calculated
using the Wilson score method [27]. Data analysis was
performed using STATA (version 11.0, StataCorp LP,
TX, USA).
Results
Demographic and clinical characteristics
A total of 2,327 specimens (295 isolates and 2,032 CSF)
collected from children in China, 626 (26.9%), Korea,
700 (30.1%) and Vietnam, 1001 (43.0%) were processed
for nucleic acid testing. Male patients constituted 63.6%
of enrolled subjects. Among children aged < 5 years,
more than half (n = 1,392) were infants aged < 1 year
(including 332 who were < 1 month of age, 772 aged
1–6 months, and 288 aged 7–11 months). Among 295
bacterial isolates, 10 isolates in Vietnam were con-
firmed as N. meningitidis. Of these, one patient was
younger than one month old, one was 1–6 months of
age, four were 7–11 months of age, and four patients
were 12–35 months of age. Five of the culture-
confirmed patients were male and half were female.
Among the 2,032 cerebrospinal fluid (CSF) specimens
tested, 14% (n = 284) were confirmed by N. meningitidis
PCR targeting the ctrA gene, including 67 patients
(11.4%) in China, 92 (13.2%) in Korea, and 125 (14.2%)
in Vietnam. S. pneumoniae and Haemphilus influenzae
type b (Hib) were identified as well (Table 1). Among
those with N. meningitidis PCR-confirmed infection, 26
specimens (11 in China and 15 in Vietnam) could not
be linked with the original clinical database due to
missing variables, resulting in a total of 258 meningo-
coccal meningitis patients with complete data available
for further analysis.
Overall, the mean age of children with N. meningitidis
PCR-confirmed meningitis was 14.4 (± 17.7) months,
with a mean age of 17.4 (± 19.2) months among females
versus 12.6 (± 16.5) months among in males (P < 0.05).
For all countries combined with culture confirmed and
PCR-confirmed, males accounted for 61.9% (n = 166)
and females were 38.1% (n = 102, P < 0.05). Approxi-
mately half of the N. meningitidis PCR-confirmed
patients were < 6 months of age (50.0% in China; 58.7%
in Korea; and 47.3% in Vietnam), and more than three-
quarters (75.6%) of them were young children aged
< 2 years old (Table 2).
Among patients who had PCR-confirmed meningitis,
the mean length of their hospital stay was 8.2 days
(± 11.3 SD; median stay: 6 days). At the time of initial
clinical presentation, patients exhibited severe manifes-
tations of meningitis including both fever and sepsis
(74%; n = 191), followed by seizure (36.4%; n = 94),
vomiting (33.0%; n = 85), lethargy or coma (34.0%; n =
87), stiff neck (26.0%; n = 67), irritability or confusion
(20.5%; n = 53), and bulging fontanelle (16.0%; n = 40)
(Table 2). In Korea and Vietnam, the majority (87% and
74.5%, respectively) of PCR-confirmed N. meningitidis
patients were found to have fever and sepsis upon initial
presentation, while this was less frequent (51.8%; n = 29)
in China. Seizures were notably more common among
Chinese children (53.6%; n = 30) compared with either
Korean (14.1%; n = 13) or Vietnamese (46.4%; n = 51)
children. Overall, 17.4% (n = 45) were hospitalized in
the neonatal ward or intensive care unit (5.0%; n = 13),
which might have been caused by severe clinical signs
and symptoms. Among the N. meningitidis PCR-
confirmed children, five deaths were observed. Three
deaths were identified in China within the early days
of life: one was identified at three days of age, an-
other one at one week of age, and one at 3.5 weeks
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of age. Two other deaths were identified in Vietnam,
where death occurred at two days of age and at
22.3 months of age.
During the original prospective surveillance studies,
over-the-counter use of antibiotics without a prescription
was common in each country. In Vietnam, 70.9% of N.
meningitidis PCR-confirmed patients reported antibiotic
consumption prior to hospital admission, compared with
57.6% in Korea and 41.4% in China (overall consumption
of antibiotics among the children with meningococcal
Table 1 Cerebrospinal fluid analysis of simultaneous detection of bacteria by PCR
Bacteria China Korea Vietnam Total
Number (%) Number (%) Number (%)
S. pneumoniae 27 (4.6) 29 (4.2) 41 (4.7) 97
Haemophilus Influenzae type b 12 (2.0) 38 (5.5) 146 (16.6) 196
N. meningitidis 67 (11.4) 92 (13.2) 125 (14.2) 284
None Detected 511 (87.0) 538 (77.1) 566 (64.5) 1615
Total 587 (100)* 608 (100)* 837 (100)* 2032
*30 (China), 89 (Korea), 41 (Vietnam) CSF specimens were positive for more than two bacterial species; **total number was subtracted 160 from 2192 that was
more than two bacterial species among three countries.
Table 2 Meningococcal meningitis among children aged < 60 months in China, Korea and Vietnam by age and gender
group, 1999 through 2002*
Characteristics PCR-confirmed Culture-confirmed Total
China Korea Vietnam Vietnam
(n = 56) (n = 92) (n = 110) (n = 10) (n = 268)b
N (%) N (%) N (%) N (%) N (%)
Age (months)
< 1 17 (30.4) 28 (30.4) 23 (20.9) 1 (10.0) 69 (25.7)
1-6 11 (19.6) 26 (28.3) 29 (26.4) 1 (10.0) 67 (25.0)
7-11 5 (8.9) 4 (4.3) 21 (19.1) 4 (40.0) 34 (12.7)
12-23 11 (19.6) 11 (12.0) 9 (8.2) 3 (30.0) 34 (12.7)
24-35 3 (5.4) 4 (4.3) 8 (7.3) 1 (10.0) 16 (6.0)
36-47 6 (10.7) 11 (12.0) 11 (10.0) 0 28 (10.4)
48-59 3 (5.4) 8 (8.7) 9 (8.2) 0 20 (7.5)
Gender
Female 13 (23.2) 31 (33.7) 53 (48.2) 5 (50.0) 102 (38.1)
Male 43 (76.8) 61 (66.3) 57 (51.8) 5 (50.0) 166 (61.9)
Clinical features
Lethargy/coma 19 (33.9) 8 (8.7) 60 (54.5) 4 (40.0) 91 (34.0)
Irritability/confusion 17 (30.4) 7 (7.6) 29 (26.4) 4 (40.0) 57 (21.3)
Nuchal rigidity 17 (30.4) 7 (7.6) 43 (39.1) 6 (60.0) 71 (26.5)
Seizure 30 (53.6) 13 (14.1) 51 (46.4) 4 (40.0) 98 (36.6)
Vomiting 3 (5.4) 18 (19.6) 64 (58.2) 7 (70.0) 92 (34.3)
Bulging fontanelle 8 (14.3) 1 (1.1) 31 (28.2) 2 (20.0) 42 (15.7)
Fever or septic appearance 29 (51.8) 80 (87.0) 82 (74.5) 9 (90.0) 200 (74.6)
Outcome
Alive 53 (94.6) UK UK 8 (80.0) NA
Deceased 3 (5.4) UK UK 2 (20.0) NA
Prior antibiotic usage
Yes 23 (41.1) 53 (57.6) 78 (70.9) 10 (100.0) 164 (61.2)
aSurveillance periods: China, January 1, 2000--December 31, 2002; South Korea: September 1, 1999--December 31, 2001; Vietnam: March 4, 2000-March 3, 2002.
b26 specimens (China, n = 11; Vietnam, n = 15) could not be linked with the clinical database were excluded from analysis.
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disease in the three sites including culture-confirmed
patients, 61.2% [164/258]).
Incidence rates
The incidence rates of N. meningitidis by culture and
serogroup-specific PCR and sequencing was highest in
Vietnam at 7.4/100,000 population (95% CI, 3.6-15.3),
followed by Korea 6.8/100,000 (95% CI, 3.5-13.5) and
China 2.1/100,000 (95% CI, 0.7-6.2) (Table 3). In China
and Korea, age-specific incidence rates were highest in
children aged < 6 months, whilst in Vietnam, rates were
highest in those aged < 12 months. Of these, there was a
particularly high incidence rate of meningococcal men-
ingitis among very young infants aged less than one
month of age: in China, Korea, and Vietnam incidence
was 96/100,000 (95% CI, 29.7-309.4), 81.5/100,000 (95%
CI, 18.8-352.2), and 36.2/100,000 (95% CI, 3.8-346.0), re-
spectively. Consequently, the incidence rate was highest
in children during the first year of life in all three coun-
tries (Table 3).
With respect to monthly distributions, we found that
N. meningitidis cases increased during May through
August in China and peaked sharply from March
to June in Vietnam. In Korea, the number of N.
meningitidis cases was highest from February through
April (data not shown).
PCR results and serogroup
All 10 meningococcal serogroup B among isolates origi-
nated from Vietnam and two CSF specimens from
Vietnam contained the allele type 140, 5, 9, 173, 175, 34,
165 (in the order abcZ, adk, aroE, fumC, gdh, pdhC, and
pgm), which has been designated as sequence type (ST)
1576 (Additional file 1: Tables S2 and S3). CSF speci-
mens that were N. meningitidis PCR-positive for ctrA
and positive for serogroup identification by PCR, but
negative by MLST were further analyzed by PCR for the
presence of crgA, IS1106, and N. meningitidis specific
16S rRNA.
A total of 44N. meningitidis PCR-positive CSF were
serogrouped, but one did not link to clinical data,
resulting in 43 specimens with complete serogroup and
clinical information available for further analysis. Of
these, 20 (91%) CSFs from Vietnam were found to have
N. meningitidis serogroup C, and two (9%) were positive
for serogroup B. In contrast, serogroups X and Y were
prevalent in China (50% [n = 3] X and 33% Y [n = 2]),
while serogroup X comprised 56% [n = 9] and serogroup
Y [n = 6] comprised 38% in Korea (Table 4). Eighty-four
percent of the CSF specimens that were positive by the
N. meningitidis PCR targeting the ctrA gene could not be
serogrouped. Among the 43 children with N. meningitidis
PCR-positive CSF and complete demographic data,
48.8% (n = 21) were less than six months of
age (Figure 1). In China, among the 6 children whose
specimens could be serogrouped, five were less than
one month of age and one was < 12 months of age.
Among the 16N. meningitidis PCR-positive Korean
children whose specimens could be serogrouped,
seven were < 6 month of age and two were < 2 years
of age, and the remaining seven were older than two
years of age. In Vietnam, of the 21N. meningitidis
PCR-positive and serogrouped children, five were
< 1 month of age, four were 1–6 months of age, five
were <12 months of age, and seven children were
older than one year of age (Figure 1).
Further analyses were conducted. Two serogroup B
positive CSF specimens in Vietnam also showed positive
results in N. meningitidis MLST analysis. However, the
43N. meningitidis ctrA positive CSF specimens that
were also positive by serogrouping PCR assay showed
negative results in the N. meningitidis MLST. Among
the 20N. meningitidis serogroup C positive CSF speci-
mens collected in Vietnam, 16 were positive for crgA
detection, 5 were positive for IS1106 detection, and 2
showed positive results in detection of 16S rRNA
(Additional file 1: Table S2).
Discussion
This is the first and largest collection of CSF specimens
obtained during population-based studies in representa-
tive populations of Asian children that provides
Table 3 Incidence of meningococcal meningitis by culture (n = 10) and serogroup-specific PCR and sequencing (n = 43)
among children aged < 5 years old in China, South Korea, and Vietnam by age group, 1999 through 2002a
Age
(months)
China Korea Vietnam
N Incidence rate (95% CI) N Incidence rate (95% CI) N Incidence rate (95% CI)
< 6 5 14.6 (4.5-47.2) 7 27.2 (9.9-74.2) 11 15.5 (3.6-67.2)
7-11 1 3.4 (0.4-33.0) 0 0 9 29.1 (8.0-106.0)
12-23 0 0 2 4.5 (0.8-25.8) 5 13.7 (3.8-50.1)
24-59 0 0 7 4.8 (1.8-13.1) 6 2.4 (0.5-10.2)
overall 6 2.1 (0.7-6.2) 16 6.8 (3.5-13.5) 31 7.4 (3.6-15.3)
aSurveillance periods: China, January 1, 2000--December 31, 2002; South Korea: September 1, 1999--December 31, 2001; Vietnam: March 4, 2000-March 3, 2002
bIncidence rates are shown per 100,000 children; 95% confidence intervals are shown in parentheses.
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laboratory-confirmed meningococcal meningitis inci-
dence rates based on molecular diagnostic technologies.
The application of modern molecular diagnostics for N.
meningitidis identified case clusters of meningococcal
serogroup B meningitis and an additional high number
of serogroup X and Y meningococcal meningitis that
had been previously unrecognized when CSFs were
tested only by culture and antigen detection methods
alone during the original surveillance study periods. Our
findings suggest that retrospective molecular analyses of
well-preserved clinical specimens in a biorepository pro-
vide novel insights into causes of childhood meningitis
that are potentially vaccine-preventable diseases, particu-
larly among patients who may commonly use antibiotics.
Based on the combined testing of CSFs by bacterial
culture and PCR, this study demonstrated that 75.6% of
the children identified with N. meningitidis in CSF were
less than 2 years of age: this occurred particularly among
infants less than 6 months of age and even in neonates.
Previous incidence studies of N. meningitidis among
children have demonstrated a sizable disease burden.
For example, among children under 4 years of age in
the United Kingdom [28], rates of serogroup B menin-
gococcal infections peaked among infants aged less than
one year of age with, accounting for almost 90% of la-
boratory confirmed cases. There is still no licensed vac-
cine available to protect against serogroup B disease
and Active Bacterial Core surveillance (ABCs) data in
the United States estimated that infants aged < 1 year
had the highest rates of meningococcal disease at 5.38
cases per 100,000 population in 1998–2007 [29]. In
Romania, children aged < 5 years old were found to
have a meningococcal meningitis incidence rate of 22
per 100,000 annually based on prospective population-
based surveillance in 2000–2002 [30].
In spite of reports of sporadic or outbreak-associated
meningococcal disease in Asia, there are limited data on
meningococcal incidence rates and on N. meningitidis ser-
ogroup distribution. In Korea, there is an estimated annual
incidence of 2.2 per 100,000 among 550,000 soldiers [14];
a nationwide study among 17 university hospitals also
reported bacteria-proven meningococcal meningitis in
125 cases from 1996 to 2005. Of these, two (1.6%) were
less than one month of age [31]. Available study identified
Table 4 Serogroup distributions of N. Meningitidis among
Cerebrospinal fluid specimens and bacterial isolates
among children aged < 5 years old in China, South
Korea, and Vietnam by age group, 1999 through 2002a
Serogroup Cerebrospinal fluid Bacterial isolates
China Korea Vietnam Vietnam
N (%) N (%)
A 0 0 0 0
B 0 0 2 (9.1) 10 (100)
C 0 1 (6.3) 20 (90.9) 0
W-135 1 (16.7) 0 0 0
X 3 (50.0) 9 (56.3) 0 0
Y 2 (33.3) 6 (37.5) 0 0
Total 6 (100) 16 (100) 22 (100) b 10 (100)
aSurveillance periods: China, January 1, 2000--December 31, 2002; South Korea:
September 1, 1999--December 31, 2001; Vietnam: March 4, 2000-March 3, 2002.
bOne specimen could not be linked with the clinical database.
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Figure 1 Number and cumulative percentage of meningococcal meningitis from PCR confirmation with ctrA gene by age group
among children aged < 5 years old in China, South Korea, and Vietnam by age group, 1999 through 2002 a. a Surveillance periods:
January 1, 2000-December 31, 2002, China; September 1, 1999-December 31, 2001 (4-month hiatus, August to November 2000), Korea; March 4,
2000-March 3, 2002, Vietnam.
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outbreaks of N. meningitidis in southern province in
Vietnam [32].
Our findings describing the meningococcal serogroup
distribution are inconsistent with previous studies. For
example, there have been no reports on serogroup X in
Asia in the past 50 years [13]. There is also a recent in-
crease in serogroup B, C, and Y predominating in
Europe, the United States, and Australia, whilst ser-
ogroup A is prevalent in Africa and Asia [12,13,33]. All
of the bacterial isolates in Vietnam from our analysis were
serotype B, which is the most commonly identified ser-
ogroup in infants in endemic settings. Prolonged out-
breaks of serogroup B disease in some countries have also
caused substantial morbidity and mortality [34,35] and
there is presently no available vaccine against this ser-
ogroup [2,30,36]. The occurrence of a cluster of serogroup
B meningococcal meningitis in Vietnam underscores the
need for further investigation of epidemiologic factors and
transmission dynamics that drive circulation of meningo-
coccal serogroups. In addition, a substantial number of
serogroup X and Y in China and Korea was identified in
the present study, suggesting that serogroup X may have
been previously under-detected due to limited surveillance
or limited availability of assays capable of detecting ser-
ogroup X. Among the three countries, N. meningitidis
was responsible for very large epidemics in China, leading
to the development and introduction of serogroup A and
C meningococcal polysaccharide vaccines for children
starting in the 1980s [37]. Nonetheless and in spite of the
vaccine having been introduced in China, there have been
sporadic outbreaks and increased cases of circulating ser-
ogroup A and C infections in 2003–2006 [38]. There have
also been continuous reports of serogroup B infections,
which have been confirmed with modern molecular diag-
nostics [37-39]. In Korea, our results showed a unique ser-
ogroup distribution (serogroup X [9/16], Y [6/16] and C
[1/16]), relative to a previous study that reported ser-
ogroup Y as the most frequently detected serogroup (9/11
isolates). Another study found one serogroup A and two
serogroup C strains among ten crg A PCR positive speci-
mens [14,40]. Current available vaccines target serogroups
A, B, C, and W-135 [12,41], but do not cover serogroups
X and Y. The results from our analysis suggest that exist-
ing knowledge gaps may be filled through the application
of systematic surveillance that applies molecular diagnos-
tic techniques for detection of N. meningitidis. The appli-
cation of molecular testing for meningococcus has had a
substantial impact in our understanding epidemiologic
patterns of meningococcus in Asia and the potential role
of contemporary available meningococcal vaccines.
Clinically, our CSF analysis confirms that infants and
young age groups were particularly vulnerable to menin-
gococcal meningitis, suffering severe signs and symptoms,
including sepsis, seizure, coma and lethargy, and vomiting.
Our findings are intriguing given the limited number
of previous studies that have reported N. meningitidis
infection in neonates and young infants [33,42,43].
These new results suggest the need to improve surveil-
lance for meningitis among infants and to consider the
role of meningococcal vaccines among infants [12,41].
Although this study provides one of the largest CSF
analyses to describe N. meningitidis in Asian countries,
there are some limitations. For example, 84.1% of the N.
meningitidis positive CSF specimens could not be sero-
grouped and may have resulted from partial degradation
of pathogen components during storage. In addition,
some specimen testing may have been limited by pro-
longed storage that was associated with diminution of
specimen volume through evaporation or prolonged
storage. Second, although original studies were done in
representative populations, rates of meningococcal men-
ingitis among children in other parts of each country
and in other countries in Asia may differ from those
found in this analysis. Third, overall reduced detection
of bacterial pathogens, including common invasive spe-
cies causing meningitis in children, may, at least in part,
be the result of widespread antibiotic overuse that was
observed throughout each study site in China, Korea
and Vietnam. In spite of the easy access to antibiotics in
these three countries, an 11.6% fatality prevailed and
remains poorly understood.
Conclusions
The burden of N. meningitidis-associated meningitis
among Asian children aged < 5 years old was found to
be substantially higher than previously reported. Inci-
dence rates among neonates and infants suggest that
meningococcal meningitis may be affecting a younger
age range of patients than previously understood. By
understanding the dynamics of N. meningitidis, with in-
corporation of routine PCR methods for detection of N.
meningitidis and the use of standardized surveillance
methods for meningococcal meningitis, many countries
will have the capacity to more accurately describe and
mitigate invasive meningococcal disease. This may be of
patients particularly true in areas with high antimicrobial
usage in developing or middle income countries, where
laboratory culture capacity may be limited. To date, more
than a decade after the original prospective surveillance
studies were completed, there have been few improve-
ments in surveillance for N. meningitidis across Asia. In
addition, given these observations, it is likely that new sur-
veillance may uncover additional serogroups, including
those identified in the results presented here. Therefore,
we strongly advocate for a pan-Asian surveillance strategy
focused on meningococcal meningitis to better under-
stand the epidemiology and to implement prevention
strategies (e.g., vaccines) in this region.
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identifications in CSF specimens, in China, South Korea, and Vietnam,
1999 through 2002. S3. Multi-locus sequence typing (MLST) results of 10
N. meningitidis isolates and 2 CSF specimens collected in Vietnam.
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